The 2023 European Obstructive Airway Diseases medicine market saw Italy leading with sales at €1.04 billion, followed by Belgium (€0.3152 billion), Austria (€0.1923 billion), Slovakia (€0.0421 billion), and Estonia (€0.0121 billion). Significant year-on-year fluctuations occurred, with Austria experiencing the highest growth at 4.38%, Belgium at 3.77%, and Estonia at 3.48%. Italy saw a modest increase of 0.75%, while Slovakia faced a contraction of -0.61%. Over the past five years, the compound annual growth rate has shown varied trends among these countries.
Future trends to watch for include:
• Investment in R&D for newer therapeutic options and personalized medicines.
• The impact of healthcare policy changes and reimbursement frameworks on market dynamics.
• Increasing prevalence of obstructive airway diseases boosting demand, especially in larger markets like Italy and Belgium.
• Technological advancements in diagnostics improving early diagnosis and treatment uptake.
• Expansion strategies of pharmaceutical companies in smaller markets like Slovakia and Estonia, potentially increasing their sales figures.
Top countries in Obstructive Airway Diseases Medicine Sales by Country
| # | 5 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 1,040 | 2023 | +1.9% | +0.75% | View data |
| 2 | 2 Belgium | 315.2 | 2023 | +1.91% | +3.77% | View data |
| 3 | 3 Austria | 192.3 | 2023 | +3.55% | +4.38% | View data |
| 4 | 4 Slovakia | 42.1 | 2023 | +0.96% | -0.61% | View data |
| 5 | 5 Estonia | 12.1 | 2023 | +4.31% | +3.48% | View data |
